Description: SARS-CoV2 will impact our post-pandemic future. Morbidity more than mortality will impact the life and health business in the mid-term. But how does this temporary disruption in health care elicit long-tail implications on other common diseases and changes in lifestyles? Find out how mid-term pricing could be affected using one case scenario and also show how mental health will particularly shape the post-pandemic future (individually and societal), not only due to long COVID. Review the experience of the insured policies and discuss future ideas for COVID-19 research at the Society of Actuaries Research Institute. Consider recent causes of death studies, as well as reported claims analyses to help expedite the analysis of recent experience. Join us where experts from both the medical and actuarial disciplines join forces to discuss this important topic.

Description: You’ve written the position papers, updated the models, and designed the required disclosures, but you may be wondering how to explain the results during interim financial reporting periods to company management as well as other stakeholders. This session will explore ways to adapt existing management reporting and offer ideas for new metrics. We will explore various methods for analyzing DAC amortization patterns, market risk benefit reserve patterns, and Liability for Future Benefits (LFPB) movements. In addition, this session will explore ways to integrate changes in LDTI with business planning and other broader business issues such as product pricing considerations and reinsurance strategy.

Description: This session will kick off the key National Association of Insurance Commissioners (NAIC) activities with a primary focus on updates to principle-based reserve valuations and appointed actuary topics. Hear insights into the current set of activities and initiatives being considered and/or adopted by the NAIC Life Actuarial Task Force (LATF) and the NAIC Risk Based Capital Working Group as well as Actuarial Standards Board. In addition, other actuarial practice issues and other appointed actuary and opinion topics relevant to life insurance, variable annuities and fixed annuities will be discussed. By the end of the session, attendees will understand what changes are being made to reserves, RBC, PBR and actuarial standards and related topics, and the anticipated timing of such emerging changes.

Description: This will be an engaging and interactive session that will begin with a game show to level set basic knowledge of LDTI. Next, you will have an opportunity to ask the experts in-depth questions about anything related to LDTI. Finally, we will invite the 2023 adopters to share their experiences with the 2025 adopters. The exact content will be driven by participants but is expected to include MRB valuation approaches, LFPB reinsurance topics, DPL, DAC, and disclosure topics. At the end of the session, participants will understand different perspectives from industry experts and peers on the many facets of LDTI.

Description: Join us for this popular annual webcast covering the latest considerations for the year's U.S. statutory financial reporting work. Get ready to hear from three expert speakers, who will discuss cash flow testing and this year’s New York and California holiday letters, the impact of recent interest rate changes including treatment of negative IMR, potential changes to statutory financial reporting due to climate change, and updates regarding Principle Based Reserves.

Description: Human longevity is one of the great success stories of the past century, and there is growing consensus that there are further gains to come. What will these future gains look like, where will they come from and how likely are they to happen. Furthermore, how do we as actuaries deal with the uncertainty when trying to predict future long-term mortality improvements more than 20 years into the future. This is one of the most important assumptions on the balance sheet that insurers and reinsurers make, so it is important to have a strong perspective on it. Our presentation will give attendees a view into some of the core components of how to assess long-term mortality improvements by looking at the cyclical nature across different countries of life expectancy. It will also deep dive into the different drivers of life expectancy over the past cycle driven largely by improved diagnosis and treatment of cardiovascular disease (CVD) and cessation of smoking, which ended in about 2010. It will then discuss how population mortality improvement has slowed and plateaued in many major countries.

Description: Statutory and GAAP metrics are useful for external audiences such as regulators and investors since they provide a consistent framework for viewing and comparing multiple companies at a point in time. However, their uses are more limited for managers who require more real-time information in making strategic decisions. Many insurers are developing internal metrics such as Value of New Business (VNB) for better profitability insights at the point of sale, to understand how new business profitability changes over time and to allow for quicker decision making. By leveraging existing models and reporting processes, insurers can reduce the additional effort involved in applying VNB toward applications such as pricing, capital allocation and risk management. Find out more about key considerations for developing and using VNB.

Description: Mortality Improvement is fundamental to setting your mortality assumptions. Creating your own Mortality Improvement assumption may seem like a Herculean task. The truth is creating a mortality improvement assumption with tools provided by the SOA, or the Continuous Mortality Investigation (CMI) make the process easy. Leaving you with the Herculean task of deciding if the assumption you created fits your product. Expect to learn about the CMI tool and the SOA's Mortality Improvement Model (MIM) tool, how you might get data to use in those tools, and what assumptions you need to make outside of data like what will the MI be in 20 or 30 years? Whether it is the general population, a segment of the general population, or certain causes of death, you will get very different answers.

Description: Explore the National Academy of Medicine’s Global Roadmap for Healthy Longevity.AARP has been a primary sponsor of the Roadmap. The Roadmap defines Healthy Longevity as when years of good health approach the biological life span, with physical, cognitive, and social functioning that enables well-being and establishes 2050 as the target year to achieve this goal globally. This Roadmap establishes five overarching principles for healthy longevity.

Description: General Session